One of the more cumbersome tasks for study teams is to manage the user administration and provisioning process into all of the technologies used to conduct clinical trials today. ePharmaSolutions has developed a solution to streamline this process to one set of credentials and one technology solution regardless of the number of vendors involved in a given study.
"The Vendor Integration Manager (VIM) is now being used on dozens of studies and provides study teams with a single user interface to manage the user provisioning process," stated Lance Converse, ePharmaSolutions founder and CEO. "Our clients complained about the need to complete up to 10 different spreadsheets each time a user is added or edited through the study, which on large studies is a difficult task that is ridden with errors," Converse added.
A typical clinical study can require up to 10 unique technology vendors that each has their own account activation and user provisioning forms and processes. This is cumbersome for clinical study managers conducting large studies who are required to complete these forms each time a user is added or edited throughout a study. For larger studies, access control to as many as 4,000 unique users in 10 systems with different roles and naming conventions must be maintained and updated in a validated environment.
"The Vendor Integration Manager works as the system of record for each user in the study and auto-completes each technology vendor's user account provisioning forms in the exact format and process they require saving study teams an enormous amount of time and avoiding countless mistakes," Converse said.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.